奥翔药业(603229.SH)：甲磺酸仑伐替尼胶囊获得英国上市许可

智通财经06-30

智通财经APP讯，奥翔药业(603229.SH)发布公告，近日，公司合作伙伴STADA Arzneimittel AG(以下简称“STADA”)的子公司THORNTON & ROSS LIMITED 收到英国药品和健康产品管理局(MHRA)核准签发的甲磺酸仑伐替尼胶囊上市许可。

甲磺酸仑伐替尼胶囊是多靶点酪氨酸激酶抑制剂(TKI)。单药用于未接受过全身治疗的不可切除肝细胞癌、放射性碘难治分化型甲状腺癌;联合依维莫司用于经一线抗血管治疗的晚期肾细胞癌;联合帕博利珠单抗一线治疗晚期肾细胞癌，也可用于经前线治疗进展的晚期子宫内膜癌(该适应症适用于错配修复正常患者)。作为常用抗血管生成靶向药，仑伐替尼可选择性抑制VEGFR、FGFR等多类激酶，阻断肿瘤血管生成通路，抑制血管新生与肿瘤增殖，具备广谱抗肿瘤活性。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2647536258?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-30 16:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647536258","market":"hk","top_or_hot":-1,"title":"奥翔药业(603229.SH)：甲磺酸仑伐替尼胶囊获得英国上市许可","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/603229\">奥翔药业</a>(603229.SH)发布公告，近日，公司合作伙伴STADA Arzneimittel AG(以下简称“STADA”)的子公司THORNTON &amp; ROSS LIMITED 收到英国药品和健康产品管理局(MHRA)核准签发的甲磺酸仑伐替尼胶囊上市许可。</p><p>甲磺酸仑伐替尼胶囊是多靶点酪氨酸激酶抑制剂(TKI)。单药用于未接受过全身治疗的不可切除肝细胞癌、放射性碘难治分化型甲状腺癌;联合依维莫司用于经一线抗血管治疗的晚期肾细胞癌;联合帕博利珠单抗一线治疗晚期肾细胞癌，也可用于经前线治疗进展的晚期子宫内膜癌(该适应症适用于错配修复正常患者)。作为常用抗血管生成靶向药，仑伐替尼可选择性抑制VEGFR、FGFR等多类激酶，阻断肿瘤血管生成通路，抑制血管新生与肿瘤增殖，具备广谱抗肿瘤活性。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>奥翔药业(603229.SH)：甲磺酸仑伐替尼胶囊获得英国上市许可</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n奥翔药业(603229.SH)：甲磺酸仑伐替尼胶囊获得英国上市许可\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/603229\">奥翔药业</a>(603229.SH)发布公告，近日，公司合作伙伴STADA Arzneimittel AG(以下简称“STADA”)的子公司THORNTON &amp; ROSS LIMITED 收到英国药品和健康产品管理局(MHRA)核准签发的甲磺酸仑伐替尼胶囊上市许可。</p><p>甲磺酸仑伐替尼胶囊是多靶点酪氨酸激酶抑制剂(TKI)。单药用于未接受过全身治疗的不可切除肝细胞癌、放射性碘难治分化型甲状腺癌;联合依维莫司用于经一线抗血管治疗的晚期肾细胞癌;联合帕博利珠单抗一线治疗晚期肾细胞癌，也可用于经前线治疗进展的晚期子宫内膜癌(该适应症适用于错配修复正常患者)。作为常用抗血管生成靶向药，仑伐替尼可选择性抑制VEGFR、FGFR等多类激酶，阻断肿瘤血管生成通路，抑制血管新生与肿瘤增殖，具备广谱抗肿瘤活性。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1461133.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"603229","symbol_name":"奥翔药业","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1461133.html","article_id":"2647536258","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647536258","pubTimestamp":1782809476,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，奥翔药业 发布公告，近日，公司合作伙伴STADA Arzneimittel AG的子公司THORNTON & ROSS LIMITED 收到英国药品和健康产品管理局核准签发的甲磺酸仑伐替尼胶囊上市许可。甲磺酸仑伐替尼胶囊是多靶点酪氨酸激酶抑制剂。作为常用抗血管生成靶向药，仑伐替尼可选择性抑制VEGFR、FGFR等多类激酶，阻断肿瘤血管生成通路，抑制血管新生与肿瘤增殖，具备广谱抗肿瘤活性。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603229":"奥翔药业","BK0239":"医药制造","IPOS":"Renaissance International IPO ETF"},"translate_title":"Aoxiang Pharmaceutical (603229.SH): Lenvatinib mesylate capsules obtained UK marketing authorization","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603229":1.5,"IPOS":1.5},"content_text":"智通财经APP讯，奥翔药业(603229.SH)发布公告，近日，公司合作伙伴STADA Arzneimittel AG(以下简称“STADA”)的子公司THORNTON & ROSS LIMITED 收到英国药品和健康产品管理局(MHRA)核准签发的甲磺酸仑伐替尼胶囊上市许可。甲磺酸仑伐替尼胶囊是多靶点酪氨酸激酶抑制剂(TKI)。单药用于未接受过全身治疗的不可切除肝细胞癌、放射性碘难治分化型甲状腺癌;联合依维莫司用于经一线抗血管治疗的晚期肾细胞癌;联合帕博利珠单抗一线治疗晚期肾细胞癌，也可用于经前线治疗进展的晚期子宫内膜癌(该适应症适用于错配修复正常患者)。作为常用抗血管生成靶向药，仑伐替尼可选择性抑制VEGFR、FGFR等多类激酶，阻断肿瘤血管生成通路，抑制血管新生与肿瘤增殖，具备广谱抗肿瘤活性。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2647536258","isCrawlerRequest":true}